<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To characterize <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> with del(13q), we reviewed clinical records of 22 <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> patients possessing del(13q) alone or del(13q) plus other abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> del(13q) patients were diagnosed with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>-unclassified due to the absence of apparent <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Elevated <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi>-anchored protein-deficient blood cell percentages were detected in <z:hpo ids='HP_0000001'>all</z:hpo> 16 with del(13q) alone and 3 of 6 (50%) patients with del(13q) plus other abnormalities </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 14 patients with del(13q) alone and 2 of 5 (40%) patients with del(13q) plus other abnormalities responded to immunosuppressive therapy with 10-year overall survival rates of 83% and 67%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Only 2 patients who had abnormalities in addition to the del(13q) abnormality developed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Given that <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>-unclassified with del(13q) is a benign <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> subset characterized by good response to immunosuppressive therapy and a high prevalence of increased <z:chebi fb="0" ids="24410">glycosylphosphatidylinositol</z:chebi>-anchored protein-deficient cells, del(13q) should not be considered an intermediate-risk chromosomal abnormality </plain></SENT>
</text></document>